Safety and efficacy of weekly adalimumab 80 mg therapy in pediatric Crohn's disease
Journal of Pediatric Gastroenterology and Nutrition · 2026-06 · 82 (6) · 1427-1434
DOI: 10.1002/jpn3.70397 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 15.03.2026. Verfasst von Eyal Cohen-Sela und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Adalimumab, Anti-Inflammatory Agents, Crohn Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: None.
Abstract (Originalsprache)
Objectives
Adalimumab is commonly used to induce and maintain remission in pediatric Crohn's disease (CD). However, data on the efficacy and safety of high‐dose adalimumab in this population are limited. This study aimed to evaluate the therapeutic effectiveness and safety of weekly high‐dose adalimumab (80 mg) in pediatric CD patients.
Methods
This multicenter retrospective study included pediatric patients with CD who received adalimumab 80 mg weekly for more than 30 days following suboptimal response to standard dosing between 2014 and 2023. Clinical and biochemical outcomes, treatment durability, and adverse events (AEs) were assessed at predefined time points. Regression analyses were used to explore predictors of sustained corticosteroid‐free remission (SCFR) and clinical response.
Results
Thirty‐eight patients (71% male; median age 16.3 years [interquartile range, IQR: 14.3–16.9]) underwent dose intensification. Ileocolonic CD was observed in 53%, and 29% had perianal disease. Clinical remission at 12 months was achieved in 50% of patients. Among the 27 patients (71%) with available adalimumab trough concentrations (ATC), 74% reached a therapeutic level (≥7.5 µg/mL) at 1 year. No significant predictors of SCFR or clinical response were identified. Early post‐intensification drug levels predicted 12‐month remission (AUC = 0.76), with an optimal threshold of 11.3 µg/mL (sensitivity 85%, specificity 67%). Treatment was de‐escalated in 5% and discontinued in 26% due to primary nonresponse. AEs occurred in 13%, mainly mild dermatologic reactions.
Conclusions
Weekly 80 mg adalimumab appears to be an effective and well‐tolerated intensification strategy in pediatric CD patients with pharmacokinetic loss of response. Further prospective studies are needed to confirm these findings and guide optimal use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Pediatric Gastroenterology Institute, Dana-Dwek Children's Hospital, Tel Aviv, Israel.
- The Pediatric Gastroenterology Unit, Emek Medical Center, Afula, Israel.
- The Rappaport Faculty of Medicine Technion-Israel Institute of Technology, Haifa, Israel.
- The Juliet Keidan Institute of Gastroenterology, Hepatology and Nutrition, Shaare Zedek Medical Center, Jerusalem, Israel.
- Pediatric Gastroenterology Unit, Soroka Medical Center, Beer Sheva, Israel.
ORCID-Profile: Manar Matar
Förderung
- None
Zitieren
APA
Cohen-Sela, E., Yerushalmy-Feler, A., Rinawi, F., Orlanski-Meyer, E., Nassar, R., Magen-Rimon, R., Weintraub, Y., Shamir, R., Shouval, D. S., & Matar, M. (2026). Safety and efficacy of weekly adalimumab 80 mg therapy in pediatric Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition, 82(6), 1427-1434. https://doi.org/10.1002/jpn3.70397
Vancouver
Cohen-Sela E, Yerushalmy-Feler A, Rinawi F, Orlanski-Meyer E, Nassar R, Magen-Rimon R, et al. Safety and efficacy of weekly adalimumab 80 mg therapy in pediatric Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition. 2026;82(6):1427-1434. doi:10.1002/jpn3.70397
BibTeX
@article{CohenSela2026,
author = {Cohen-Sela, Eyal and Yerushalmy-Feler, Anat and Rinawi, Firas and Orlanski-Meyer, Esther and Nassar, Raouf and Magen-Rimon, Ramit and Weintraub, Yael and Shamir, Raanan and Shouval, Dror S and Matar, Manar},
title = {Safety and efficacy of weekly adalimumab 80 mg therapy in pediatric Crohn's disease},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
volume = {82},
number = {6},
pages = {1427--1434},
doi = {10.1002/jpn3.70397}
}
EUVIMED